Bicycle Therapeutics Company Insiders
BCYC Stock | USD 20.40 0.05 0.25% |
Bicycle Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Bicycle Therapeutics suggests that all insiders are panicking. Bicycle Therapeutics employs about 284 people. The company is managed by 15 executives with a total tenure of roughly 663 years, averaging almost 44.0 years of service per executive, having 18.93 employees per reported executive.
Bicycle Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
2024-11-11 | Travis Alvin Thompson | Disposed 6256 @ 25.11 | View | ||
2024-10-03 | Travis Alvin Thompson | Disposed 153 @ 22.26 | View | ||
2024-07-03 | Kevin Lee | Disposed 3194 @ 19.64 | View | ||
2024-04-11 | Michael Charles Ferguso Hannay | Disposed 257 @ 22.49 | View | ||
2024-04-03 | Kevin Lee | Disposed 3158 @ 23.81 | View | ||
2024-01-03 | Travis Alvin Thompson | Disposed 604 @ 17.5 | View |
Monitoring Bicycle Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Bicycle |
Bicycle Therapeutics' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Bicycle Therapeutics' future performance. Based on our forecasts, it is anticipated that Bicycle will maintain a workforce of about 280 employees by December 2024.Bicycle Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.1502) % which means that it has lost $0.1502 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2667) %, meaning that it created substantial loss on money invested by shareholders. Bicycle Therapeutics' management efficiency ratios could be used to measure how well Bicycle Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 30, 2024, Return On Tangible Assets is expected to decline to -0.32. In addition to that, Return On Capital Employed is expected to decline to -0.38. At present, Bicycle Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Assets is expected to grow to about 10.2 M, whereas Non Current Assets Total are forecasted to decline to about 18 M.As of November 30, 2024, Common Stock Shares Outstanding is expected to decline to about 23.1 M. The current year's Net Loss is expected to grow to about (96.4 M)
Bicycle Therapeutics Workforce Comparison
Bicycle Therapeutics is rated third in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 3,291. Bicycle Therapeutics holds roughly 284 in number of employees claiming about 9% of equities under Health Care industry.
Bicycle Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bicycle Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bicycle Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Bicycle Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-12-01 | 0.2143 | 3 | 14 | 2,575 | 14,047 |
2024-06-01 | 0.7778 | 7 | 9 | 19,545,630 | 2,390,006 |
2024-03-01 | 3.3 | 33 | 10 | 1,001,000 | 117,276 |
2023-09-01 | 0.1667 | 1 | 6 | 120,000 | 3,248 |
2023-03-01 | 3.8571 | 27 | 7 | 728,250 | 16,836 |
2022-03-01 | 13.5 | 27 | 2 | 600,155 | 52,000 |
2021-12-01 | 0.2857 | 4 | 14 | 165,477 | 328,843 |
2021-09-01 | 0.3538 | 23 | 65 | 232,792 | 593,978 |
2021-06-01 | 0.3548 | 11 | 31 | 116,708 | 237,482 |
2021-03-01 | 0.7826 | 18 | 23 | 769,621 | 126,285 |
2020-12-01 | 0.4444 | 4 | 9 | 35,000 | 70,000 |
2020-09-01 | 0.3333 | 1 | 3 | 120,000 | 4,744 |
2020-06-01 | 1.0 | 1 | 1 | 71,450 | 71,450 |
2019-06-01 | 1.1373 | 58 | 51 | 24,385,381 | 17,772,298 |
Bicycle Therapeutics Notable Stakeholders
A Bicycle Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bicycle Therapeutics often face trade-offs trying to please all of them. Bicycle Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bicycle Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Lee MBA | President | Profile | |
Travis Thompson | Chief VP | Profile | |
Kevin MBA | CEO Director | Profile | |
CBE FMedsci | NonEx CoFounder | Profile | |
Christian Heinis | Scientific Founder | Profile | |
Stephanie Yao | Senior Communications | Profile | |
Alistair Milnes | Chief Officer | Profile | |
Gillian Langford | Head Management | Profile | |
Alethia Young | Chief Officer | Profile | |
David CFA | Senior Communications | Profile | |
Nicholas Keen | Chief Officer | Profile | |
Dr B | Chief Officer | Profile | |
Zafar Qadir | General Counsel | Profile | |
MBA MBA | Pres CFO | Profile | |
Santiago MD | Chief Officer | Profile |
About Bicycle Therapeutics Management Performance
The success or failure of an entity such as Bicycle Therapeutics often depends on how effective the management is. Bicycle Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bicycle management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bicycle management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.30) | (0.32) | |
Return On Capital Employed | (0.36) | (0.38) | |
Return On Assets | (0.30) | (0.32) | |
Return On Equity | (0.49) | (0.51) |
Please note, the presentation of Bicycle Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bicycle Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bicycle Therapeutics' management manipulating its earnings.
Bicycle Therapeutics Workforce Analysis
Traditionally, organizations such as Bicycle Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bicycle Therapeutics within its industry.Bicycle Therapeutics Manpower Efficiency
Return on Bicycle Therapeutics Manpower
Revenue Per Employee | 95K | |
Revenue Per Executive | 1.8M | |
Net Loss Per Employee | 636.1K | |
Net Loss Per Executive | 12M | |
Working Capital Per Employee | 1.7M | |
Working Capital Per Executive | 32.8M |
Complementary Tools for Bicycle Stock analysis
When running Bicycle Therapeutics' price analysis, check to measure Bicycle Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicycle Therapeutics is operating at the current time. Most of Bicycle Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicycle Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicycle Therapeutics' price. Additionally, you may evaluate how the addition of Bicycle Therapeutics to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |